RLMD Relmada Therapeutics Inc

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

CORAL GABLES, Fla., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Wednesday, August 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024.

Conference Call and Webcast Information:

Date: Wednesday, August 7, 2024 at 4:30 PM ET

Participant Dial-in (US): 1-800-717-1738

Participant Dial-in (International): 1-646-307-1865

Conference: 39584

Webcast Access:

The conference call utilizes the “Call me™” technology

  • Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link, above, for instant telephone access to the event.
  • Call me™ link will be made active 15 minutes prior to scheduled start time.

A replay of the webcast will be available in the Investors section of the Relmada website at .

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at .

Investor Contact:

Tim McCarthy

LifeSci Advisors



EN
05/08/2024

Underlying

RLMDRelmada Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relmada Therapeutics Inc

 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results o...

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, March 19, 2026 at 4:30 PM ET to discuss financial results for the fourth quarter ended December 31, 2025, and recent business progress. Conference Call and Webcast Information: ...

March 12, 2026 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics to Present at the Leerink Partners Global Healthc...

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Leerink Partners Global Healthcare Conference being held in Miami, Florida, from March 8-11, 2026. Leerink Partners Global Healthc...

March 9, 2026 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private P...

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $160.0 million to the Company, before placement agent fees an...

March 9, 2026 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 ...

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse events and no treatment-related discontinuations Data reinforces advancement of NDV-01 into Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 C...

March 9, 2026 1 EN
 PRESS RELEASE
Free
RLMD Relmada Therape...

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignme...

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for on...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch